Ventura Cannabis & Wellness Corporation (CVHIF) Fair Value & Analysis
Healthcare · US · Market cap $3.7K
Ventura Cannabis & Wellness Corporation
CVHIF · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.5200 to $0.0001 (−100.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0001 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ventura Cannabis & Wellness Corporation (CVHIF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Ventura Cannabis & Wellness Corporation generated revenue of $10.6M at a net margin of -22.3%. Revenue declined 82.5% year over year. It earns a return on equity of -28.8%. Net debt stands at $1.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Ventura Cannabis & Wellness Corporation operates as a vertically integrated cannabis product company in California. The company was formerly known as BLVD Centers Corporation and changed its name to Ventura Cannabis & Wellness Corporation in February 2019. The company was incorporated in 2013 and is headquartered in Los Angeles, California.
Revenue & earnings trend
FY2016 – FY2020 · reported fiscal years
Ventura Cannabis & Wellness Corporation reported revenue of $10.6M in FY2020 versus $13.4M in FY2016, a compound −5.7%/yr. Reported net income was −$1.7M in FY2020.
Is CVHIF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ventura Cannabis & Wellness Corporation (CVHIF) undervalued?
What is the fair value of CVHIF?
What is the quality score of CVHIF?
What is the revenue of Ventura Cannabis & Wellness Corporation (CVHIF)?
What is the net profit margin of CVHIF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.